Indeed, several retrospective studies of patients with EGFR and or ALK mutation non-small cell lung cancer (NSCLC) treated with local ablative therapy and continued treatment with targeted therapy resulted in improved progression-free survival [17–20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.